Lumos Pharma, Inc.
LUMO · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $0 | $0 |
| % Growth | 34.7% | 562.2% | 36.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2 | $1 | $0 | $0 |
| % Margin | 100% | 96.8% | 100% | 100% |
| R&D Expenses | $22 | $18 | $16 | $9 |
| G&A Expenses | $17 | $16 | $15 | $17 |
| SG&A Expenses | $17 | $16 | $15 | $17 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $39 | $34 | $32 | $26 |
| Operating Income | -$37 | -$32 | -$31 | -$26 |
| % Margin | -1,785.2% | -2,103.7% | -13,629.1% | -15,656.5% |
| Other Income/Exp. Net | $3 | $1 | $0 | $7 |
| Pre-Tax Income | -$34 | -$31 | -$31 | -$20 |
| Tax Expense | -$0 | -$0 | -$1 | -$14 |
| Net Income | -$34 | -$31 | -$30 | -$6 |
| % Margin | -1,659.4% | -2,039.5% | -13,230.4% | -3,370.8% |
| EPS | -4.18 | -3.71 | -3.65 | -0.84 |
| % Growth | -12.7% | -1.6% | -334.5% | – |
| EPS Diluted | -4.18 | -3.71 | -3.65 | -0.84 |
| Weighted Avg Shares Out | 8 | 8 | 8 | 7 |
| Weighted Avg Shares Out Dil | 8 | 8 | 8 | 7 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | -$37 | -$32 | -$31 | -$26 |
| % Margin | -1,783% | -2,100.5% | -13,534.8% | -15,308.9% |